The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
While GlobeImmune's therapeutic vaccine for Hepatitis C is only in Phase Ib of clinical trials, their focus on immunity to the Hepatitis C virus is fascinating. GI-5005 is based on tarmogens being potent activators of antigen-specific immune responses against disease.
Continue reading »As you may recall we've been saying VX-950 is the revolutionary new therapy to watch for HCV. Now it looks like the FDA agrees this treatment is quite promising and deserving of faster approval than a lesser worthy approach. Another reason they are doing this is they know current therapy options are less than ideal.
Continue reading »It is always good to see progress with alternatives to current medical therapy for HCV. Even though companies that are... View Article
Continue reading »This is a terrific overview article regarding the AASLD meeting. Liz Highleyman did a fantastic job of condensing the key... View Article
Continue reading »Genotypes 2 and 3 are much more responsive to current interferon combination therapies. This report details studies that show a... View Article
Continue reading »Vertex is the racehorse to watch right now. They are progressing quicky on their preliminary good results. While it’s not... View Article
Continue reading »This report is an update of therapy progress presented at the AASLD (American Academy for the Study of Liver Diseases).... View Article
Continue reading »Schering and Roche are taking part in dueling press releases. Each claiming their solution is better. Either way, they seem... View Article
Continue reading »Weight-based dosing has always made sense to us. We don’t really understand why Roche has not changed their dosing to... View Article
Continue reading »The development of a HCV vaccine is very exciting, even to patients already infected. Although the vaccine will not help them direcly, it shows definite progress in understanding and outsmarting this virus that is known to be difficult to combat due to its rapid mutation. If they are making progress with a vaccine, progress for better treatment must be close behind.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
